Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other financing activities: 2015-2020

Historic Other financing activities for Agios Pharmaceuticals (AGIO) over the last 1 years, with Jun 2020 value amounting to $250.5 million.

  • Agios Pharmaceuticals' Other financing activities was N/A to $250.5 million in Q2 2020 from the same period last year, while for Jun 2020 it was $250.2 million, marking a year-over-year change of. This contributed to the annual value of $250.5 million for FY2020, which is N/A change from last year.
  • Per Agios Pharmaceuticals' latest filing, its Other financing activities stood at $250.5 million for Q2 2020, which was up 123,317.24% from $203,000 recorded in Q2 2018.
  • Agios Pharmaceuticals' Other financing activities' 5-year high stood at $250.5 million during Q2 2020, with a 5-year trough of -$727,000 in Q4 2017.
  • Moreover, its 2-year median value for Other financing activities was $203,000 (2018), whereas its average is $83.6 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Other financing activities plummeted by 785.85% in 2017 and then skyrocketed by 199.51% in 2018.
  • Over the past 4 years, Agios Pharmaceuticals' Other financing activities (Quarterly) stood at $106,000 in 2016, then crashed by 785.85% to -$727,000 in 2017, then surged by 199.51% to $203,000 in 2018, then reached $250.5 million in 2020.
  • Its Other financing activities stands at $250.5 million for Q2 2020, versus $203,000 for Q2 2018 and $188,000 for Q1 2018.